Laboratory issues in bleeding disorders

Haemophilia

Volumn 12, Issue SUPPL. 3, 2006, Pages 68-75

  Lillicrap, D ^a   Nair, S C ^b   Srivastava, A ^b   Rodeghiero, F ^c   Pabinger, I ^d   Federici, August B ^e  

^a QUEEN S UNIVERSITY   (Canada)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c SAN BORTOLO HOSPITAL   (Italy)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Acquired inhibitors of haemostasis; Bleeding score; Inherited and acquired bleeding; Screening tests; Von Willebrand's disease

Indexed keywords

ARTICLE; BLEEDING DISORDER; BLEEDING TENDENCY; BLEEDING TIME; COMPLEMENT BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOSTASIS; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; THROMBOCYTE COUNT; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; DEVELOPING COUNTRIES; FACTOR IX; FACTOR VIII; HUMANS; ISOANTIBODIES; MALE; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASES;

EID: 33646146198     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01279.x     Document Type: Article

References (35)

1. Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: An international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
2. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2006; 4: 766-73.
3. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-9.
4. Franchini M. The platelet function analyzer (PFA-100): An update on its clinical use. Clin Lab 2005; 51: 367-72.
5. Favaloro EJ, Bonar R, Sioufi J et al. Laboratory diagnosis of von Willebrand disorder. Current practice in the southern hemisphere. Am J Clin Pathol 2003; 119: 882-93.
6. Laffan M, Brown SA, Collins PW et al. The diagnosis of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217.
7. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: Variability versus "variants". Blood 1980; 56: 712-16.
8. Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost 2005; 31: 569-76.
9. Zhang L, Li H, Zhao H, Zhang X, Ji X, Yang R. Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia 2003; 9: 696-702.
10. Islam SI, Quadri MI. Spectrum of hereditary coagulation deficiencies in eastern province, Saudi Arabia. East Mediterr Health J 1999; 5: 1188-95.
11. Karimi M, Yarmohammadi H, Ardeshiri R, Yarmohammadi H. Inherited coagulation disorders in southern Iran. Haemophilia 2002; 8: 740-4.
12. Sadler JE, Mannuci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
13. Berliner SA, Seligsohn U, Zivelin A, Zwang E, Sofferman G. A relatively high frequency of severe (type III) von Willebrand disease in Israel. Br J Haematol 1986; 62: 535-43.
14. Srivastava A. Von Willebrand disease in developing countries. Semin Hematol 2005; 42: 36-41.
15. Giangrande PL, Black C. World Federation of Hemophilia programs in developing countries. Semin Thromb Hemost 2005; 31: 555-60.
16. Rodeghiero F. Von Willebrand disease: Still an intriguing disorder in the era of molecular medicine. Haemophilia 2002; 8: 292-300.
17. Sadler JE. Von Willebrand disease type 1: A diagnosis in search of a disease. Blood 2003; 101: 2089-93.
18. Castaman G, Tosetto A, Rodeghiero F. Von Willebrand disease. In: O'Shaughnessy D, Makris M, Lillicrap D, eds. Practical Hemostasis and Thrombosis Vol. 6. Williston, VT: Blackwell Publishing, 2005: 51-61.
19. Rodeghiero F, Castaman G. Von Willebrand disease: Epidemiology. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia Vol. 45. Williston, VT: Blackwell Publishing, 2005: 265-71.
20. Eikenboom J, Van Marion V, Putter H et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). J Thromb Haemost 2006; 4: 774-82.
21. Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3: 775-7.
22. Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
23. DiMichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
24. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
25. Ljung R, Petrini P, Tengborn L, Sjorin E. Haemophilia B mutations in Sweden: A population-based study of mutational heterogeneity. Br J Haematol 2001; 113: 81-6.
26. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
27. Federici AB, Rand JH, Bucciarelli P et al. Subcommittee on von Willebrand Factor Acquired von Willebrand syndrome: Data from an international registry. Thromb Haemost 2000; 84: 345-9.
28. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Willebrand syndromes: Clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 14: 401-36.
29. Warrier I, Ewenstein BM, Koerper M et al. Factor IX inhibitors and anaphylaxis in hemophilia B. Am J Pediatr Hematol Oncol 1997; 19: 23-7.
30. Sahud MA. Laboratory diagnosis of inhibitors. Semin Thromb Haemost 2000; 26: 195-203.
31. Lindgren A, Wadenvik H, Tengborn L. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia 2002; 8: 644-8.
32. Shetty S, Ghosh K, Mohanty D. ELISA for factor VIII antibodies: Does it detect antibodies much before the conventional Bethesda assay? Haemophilia 2003; 9: 654.
33. Biggs R, Bidwell E. A method for the study of antihemophiliac globulin inhibitors with reference to six cases. Br J Haematol 1959; 5: 379-95.
34. Austen DEG, Lechner K, Rizza CR, Rhymes IL. A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost 1982; 47: 72-5.
35. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor IIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.